CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $5,554,000 | +33.4% | 294,620 | +8.2% | 5.57% | +65.1% |
| Q1 2021 | $4,162,000 | +31.6% | 272,393 | +21.5% | 3.37% | +40.0% |
| Q4 2020 | $3,162,000 | -16.4% | 224,129 | -7.1% | 2.41% | -19.3% |
| Q3 2020 | $3,781,000 | -8.7% | 241,278 | +2.1% | 2.98% | +3.0% |
| Q2 2020 | $4,142,000 | +3.0% | 236,394 | -16.3% | 2.90% | -26.8% |
| Q1 2020 | $4,022,000 | -22.1% | 282,272 | +37.2% | 3.96% | +14.4% |
| Q4 2019 | $5,162,000 | – | 205,726 | – | 3.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |